Downloads: 206

Files in This Item:
File Description SizeFormat 
journal.pone.0035052.pdf232.79 kBAdobe PDFView/Open
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNishijima, Norihiroja
dc.contributor.authorMarusawa, Hiroyukija
dc.contributor.authorUeda, Yoshihideja
dc.contributor.authorTakahashi, Kenja
dc.contributor.authorNasu, Akihiroja
dc.contributor.authorOsaki, Yukioja
dc.contributor.authorKou, Tadayukija
dc.contributor.authorYazumi, Shujiroja
dc.contributor.authorFujiwara, Takeshija
dc.contributor.authorTsuchiya, Sokenja
dc.contributor.authorShimizu, Kazuharuja
dc.contributor.authorUemoto, Shinjija
dc.contributor.authorChiba, Tsutomuja
dc.contributor.alternative西島, 規浩ja
dc.contributor.alternative丸澤, 宏之ja
dc.description.abstract[Background and Aims]: Although the advent of ultra-deep sequencing technology allows for the analysis of heretofore-undetectable minor viral mutants, a limited amount of information is currently available regarding the clinical implications of hepatitis B virus (HBV) genomic heterogeneity. [Methods]: To characterize the HBV genetic heterogeneity in association with anti-viral therapy, we performed ultra-deep sequencing of full-genome HBV in the liver and serum of 19 patients with chronic viral infection, including 14 therapy-naïve and 5 nucleos(t)ide analogue(NA)-treated cases. [Results]: Most genomic changes observed in viral variants were single base substitutions and were widely distributed throughout the HBV genome. Four of eight (50%) chronic therapy-naïve HBeAg-negative patients showed a relatively low prevalence of the G1896A pre-core (pre-C) mutant in the liver tissues, suggesting that other mutations were involved in their HBeAg seroconversion. Interestingly, liver tissues in 4 of 5 (80%) of the chronic NA-treated anti-HBe-positive cases had extremely low levels of the G1896A pre-C mutant (0.0%, 0.0%, 0.1%, and 1.1%), suggesting the high sensitivity of the G1896A pre-C mutant to NA. Moreover, various abundances of clones resistant to NA were common in both the liver and serum of treatment-naïve patients, and the proportion of M204VI mutants resistant to lamivudine and entecavir expanded in response to entecavir treatment in the serum of 35.7% (5/14) of patients, suggesting the putative risk of developing drug resistance to NA. [Conclusion]: Our findings illustrate the strong advantage of deep sequencing on viral genome as a tool for dissecting the pathophysiology of HBV infection.ja
dc.publisherPublic Library of Scienceja
dc.rights© 2012 Nishijima et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ja
dc.titleDynamics of Hepatitis B Virus Quasispecies in Association with Nucleos(t)ide Analogue Treatment Determined by Ultra-Deep Sequencing.ja
dc.type.niitypeJournal Articleja
dc.identifier.jtitlePloS oneja
Appears in Collections:Journal Articles

Show simple item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.